The HIV Eradication Scientific Working Group (SWG) was created to directly address one of the high priority research areas of the OAR: ?to develop novel approaches and strategies to eliminate viral reservoirs that could lead toward a cure or lifelong remission of HIV infection?. Despite the major success of combination antiretroviral therapy (cART) in suppressing viral replication and preventing disease progression, HIV-1 infection persists in a latent reservoir, composed primarily of a long-lived population of resting memory CD4+ T cells. These latently infected cells harbor replication competent HIV-1 DNA, therefore the elimination of the latent viral reservoir is essential to eradicating HIV-1 infection. Major challenges to the elimination of the reservoir are the lack of: (i) robust, sensitive and reliable assays to accurately measure and localize the reservoir of replication-competent proviruses; (ii) basic understanding of the mechanisms that lead to latent reservoirs; and (iii) reliable methods to reactivate latent cells and to target them for killing. The HIV Eradication SWG was formed to bring together outstanding investigators who have not previously collaborated: (i) from within the three ERC-CFAR institutions; (ii) from other New York City institutions, including Columbia University Medical Center, New York University, and Icahn School of Medicine at Mount Sinai; and (iii) non-AIDS experts from other fields, to develop a multi-pronged approach to synergize basic, translational, and clinical efforts targeted towards HIV eradication. This SWG will leverage the clinical samples, assays and technologies available through the laboratory and clinical cores of the ERC-CFAR to drive research efforts to eradicate HIV-1 infection and thereby prevent new infections. This SWG aims to: (i) foster collaborations among SWG members and affiliates to focus on the molecular mechanisms of latency and on the development and evaluation of novel and alternate modalities for HIV Cure; (ii) use the ERC-CFAR cores to support and recruit experts from non-HIV/AIDS areas and Early Stage Investigators to develop innovative technologies to quantify and eradicate HIV infection; and (iii) To obtain funding for research projects that are developed through new collaborations and ideas formed in the SWG to increase our understanding of the underlying mechanisms that generate and maintain latent reservoirs and to develop reliable methods to reactivate latent cells and to target them for killing.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
1P30AI124414-01A1
Application #
9322815
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2017-05-01
Budget End
2018-04-30
Support Year
1
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Albert Einstein College of Medicine, Inc
Department
Type
DUNS #
079783367
City
Bronx
State
NY
Country
United States
Zip Code
10461
Hannaford, Alisse; Lipshie-Williams, Madeleine; Starrels, Joanna L et al. (2018) The Use of Online Posts to Identify Barriers to and Facilitators of HIV Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men: A Comparison to a Systematic Review of the Peer-Reviewed Literature. AIDS Behav 22:1080-1095
Lu, Ching-Lan; Pai, Joy A; Nogueira, Lilian et al. (2018) Relationship between intact HIV-1 proviruses in circulating CD4+ T cells and rebound viruses emerging during treatment interruption. Proc Natl Acad Sci U S A 115:E11341-E11348
Grov, Christian; Jonathan Rendina, H; Patel, Viraj V et al. (2018) Prevalence of and Factors Associated with the Use of HIV Serosorting and Other Biomedical Prevention Strategies Among Men Who Have Sex with Men in a US Nationwide Survey. AIDS Behav 22:2743-2755
Cohen, Yehuda Z; Lorenzi, Julio C C; Krassnig, Lisa et al. (2018) Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J Exp Med 215:2311-2324
Cohen, Yehuda Z; Lorenzi, Julio C C; Seaman, Michael S et al. (2018) Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. J Virol 92:
Cohen, Yehuda Z; Caskey, Marina (2018) Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection. Curr Opin HIV AIDS 13:366-373
Patel, Viraj V; Dange, Alpana; Rawat, Shruta et al. (2018) Barriers to HIV Testing Among Men Who Have Sex With Men in India Reached Online: Implications for Interventions. J Acquir Immune Defic Syndr 78:e30-e34
Liu, Yanyan; Ndumnego, Okechukwu C; Chen, Tingting et al. (2018) Soluble CD14 as a Diagnostic Biomarker for Smear-Negative HIV-Associated Tuberculosis. Pathogens 7:
Bar-On, Yotam; Gruell, Henning; Schoofs, Till et al. (2018) Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med 24:1701-1707
Bachhuber, Marcus A; Nash, Denis; Southern, William N et al. (2018) Reducing the default dispense quantity for new opioid analgesic prescriptions: study protocol for a cluster randomised controlled trial. BMJ Open 8:e019559

Showing the most recent 10 out of 27 publications